TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright

Key Points

• HC Wainwright trimmed TG Therapeutics' Q2 2026 EPS estimate to $0.27 (from $0.28) and lowered FY‑2026 through FY‑2030 earnings forecasts modestly, signaling reduced margin/growth assumptions.
• TG raised FY‑2026 revenue guidance to $875–$900 million, well above the Street, but left EPS guidance blank—creating near‑term uncertainty despite stronger top‑line expectations.
• TG reported $0.14 EPS last quarter, missing the $0.35 consensus while revenue rose ~78% to $192.6M; analysts' consensus rating is a Moderate Buy with a $50 target and a market cap near $4.66 billion.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, March 3rd. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $0.27 per share for the quarter, down from their previous forecast of $0.28. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics' Q3 2026 earnings at $0.31 EPS, FY2026 earnings at $1.21 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.37 EPS, FY2029 earnings at $2.97 EPS and FY2030 earnings at $3.91 EPS.

TGTX has been the topic of several other research reports. The Goldman Sachs Group upped their price target on TG Therapeutics from $37.00 to $39.00 and gave the company a "neutral" rating in a research note on Thursday, January 15th. Wall Street Zen cut shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. JPMorgan Chase & Co. cut their price objective on shares of TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating on the stock in a report on Monday, February 2nd. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of TG Therapeutics in a report on Monday, December 29th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.00.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $29.19 on Thursday. The stock's fifty day simple moving average is $29.75 and its 200 day simple moving average is $31.48. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 2.89. TG Therapeutics has a one year low of $25.28 and a one year high of $46.48. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of 10.54 and a beta of 1.87.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.35 by ($0.21). TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. The company had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. During the same period in the previous year, the firm posted $0.15 earnings per share. The firm's revenue for the quarter was up 78.0% compared to the same quarter last year.

Institutional Trading of TG Therapeutics

Several hedge funds have recently added to or reduced their stakes in TGTX. Johnson Financial Group Inc. acquired a new position in TG Therapeutics in the second quarter valued at about $25,000. Danske Bank A S bought a new position in shares of TG Therapeutics during the 3rd quarter valued at about $25,000. Optiver Holding B.V. grew its position in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 732 shares during the period. Bessemer Group Inc. increased its stake in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 486 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new stake in TG Therapeutics during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Key TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: TG updated FY‑2026 revenue guidance to $875.0–$900.0 million, well above the Street consensus of $784.9 million, signaling stronger top‑line expectations and supporting near‑term sentiment.
• Neutral Sentiment: The company’s FY‑2026 EPS guidance field appears blank in the release (no EPS figure provided), creating short‑term uncertainty about margin expectations even as revenue guidance was raised.
• Negative Sentiment: HC Wainwright trimmed earnings estimates across multiple periods on March 3: Q2‑2026 EPS to $0.27 (from $0.28), Q3‑2026 to $0.31 (from $0.34), Q4‑2026 to $0.41 (from $0.47), FY‑2026 to $1.21 (from $1.30) and reduced FY‑2027–FY‑2030 forecasts modestly (e.g., FY‑2027 to $1.86 from $1.95; FY‑2030 to $3.91 from $4.01). These downward revisions suggest analysts are trimming margin or growth assumptions despite stronger revenue guidance.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.